HHE Rheumatology and musculoskeletal supplement 2018 | Page 22

References 1 Tsokos GC . Systemic lupus erythematosus . N Engl J Med 2011 ; 365:2110 – 21 . 2 Rahman A , Isenberg DA . Systemic lupus erythematosus . N Engl J Med 2008 ; 358:929 – 39 . 3 Ronnblom LE et al . Autoimmunity after alphainterferon therapy for malignant carcinoid tumors . Ann Intern Med 1991 ; 115:178 – 83 . 4 King JK , Hahn BH . Systemic lupus erythematosus : modern strategies for management : a moving target . Best Pract Res Clin Rheumatol 2007 ; 21:971 – 87 . 5 Yildirim-Toruner C , Diamond B . Current and novel therapeutics in the treatment of systemic lupus erythematosus . J Allergy Clin Immunol 2011 ; 127:303 – 12 ; quiz 13 – 14 . 6 Boyce EG , Fusco BE . Belimumab : review of use in systemic lupus erythematosus . Clin Ther 2012 ; 34:1006 – 22 . 7 Parodis I , Axelsson M , Gunnarsson I . Belimumab for systemic lupus erythematosus : a practice-based view . Lupus 2013 ; 22:372 – 80 . 8 Ruiz-Irastorza G , Khamashta MA . Hydroxychloroquine : the cornerstone of lupus therapy . Lupus 2008 ; 17:271 – 3 . 9 Ruiz-Irastorza G et al . Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus : a systematic review . Ann Rheum Dis 2010 ; 69:20 – 8 . 10 Levy RA et al . Hydroxychloroquine ( HCQ ) in lupus pregnancy : double-blind and placebo-controlled study . Lupus 2001 ; 10:401 – 4 . 11 Pons-Estel GJ et al . Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis : LXV , data from a multiethnic US cohort . Arthritis Rheum 2009 ; 61:830 – 9 . 12 Hench PS et al . The effects of the adrenal cortical hormone 17-hydroxy-11- dehydrocorticosterone ( Compound E ) on the acute phase of rheumatic fever ; preliminary report . Proc Staff Meet Mayo Clin 1949 ; 24:277 – 97 . 13 Apostolopoulos D , Morand EF . It hasn ’ t gone away : the problem of glucocorticoid use in lupus remains . Rheumatology ( Oxford ) 2017 ; 56 ( suppl _ 1 ): i114-i122 . 14 Bertsias G et al . EULAR recommendations for the management of systemic lupus erythematosus . Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics . Ann Rheum Dis 2008 ; 67:195 – 205 . 15 Barile-Fabris L et al . Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus . Ann Rheum Dis 2005 ; 64:620 – 5 . 16 Contreras G et al . Maintenance therapies for proliferative lupus nephritis : mycophenolate mofetil , azathioprine and intravenous cyclophosphamide . Lupus 2005 ; 14 Suppl 1 : s33 – 8 . 17 Houssiau FA et al . Immunosuppressive therapy in lupus nephritis : the Euro-Lupus Nephritis Trial , a randomized trial of low-dose versus high-dose intravenous cyclophosphamide . Arthritis Rheum 2002 ; 46:2121 – 31 . 18 Boumpas DT et al . Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992 ; 340:741 – 5 . 19 Austin HA 3rd et al . Therapy of lupus nephritis . Controlled trial of
prednisone and cytotoxic drugs . N Engl J Med 1986 ; 314:614 – 19 . 20 Gourley MF et al . Methylprednisolone and cyclophosphamide , alone or in combination , in patients with lupus nephritis . A randomized , controlled trial . Ann Intern Med 1996 ; 125:549 – 57 . 21 Houssiau FA . Therapy of lupus nephritis : lessons learned from clinical research and daily care of patients . Arthritis Res Ther 2012 ; 14:202 . 22 Gunnarsson I et al . Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamideresistant proliferative lupus nephritis . Arthritis Rheum 2007 ; 56:1263 – 72 . 23 Mok CC . Pro : The use of calcineurin inhibitors in the treatment of lupus nephritis . Nephrol Dial Transplant 2016 ; 31:1561 – 6 . 24 Fei Y et al . Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide : a prospective cohort study . Clin Exp Rheumatol 2013 ; 31:62 – 8 . 25 Li X et al . Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis . Nephrol Dial Transplant 2012 ; 27:1467 – 72 . 26 Hannah J , Casian A , D ’ Cruz D . Tacrolimus use in lupus nephritis : A systematic review and meta-analysis . Autoimmun Rev 2016 ; 15:93 – 101 . 27 Alexander T et al . The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus . Ann Rheum Dis 2015 ; 74:1474 – 8 . 28 Monneaux F et al . T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR / lpr mice . Eur J Immunol 2003 ; 33:287 – 96 . 29 Monneaux F et al . Intramolecular T cell spreading in unprimed MRL / lpr mice : importance of the U1-70k protein sequence 131-151 . Arthritis Rheum 2004 ; 50:3232 – 8 . 30 Monneaux F et al . Selective modulation of CD4 + T cells from lupus patients by a promiscuous , protective peptide analog . J Immunol 2005 ; 175:5839 – 47 . 31 Monneaux F et al . Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus . Arthritis Res Ther 2007 ; 9 : R111 . 32 Page N et al . The spliceosomal phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by gammadelta T cells . PLoS One 2009 ; 4 : e5273 . 33 Page N et al . HSC70 blockade by the therapeutic peptide P140 affects autophagic processes and endogenous MHCII presentation in murine lupus . Ann Rheum Dis 2011 ; 70:837 – 43 . 34 Zimmer R et al . Lupuzor / P140 peptide in patients with systemic lupus erythematosus : a randomised , double-blind , placebo-controlled phase IIb clinical trial . Ann Rheum Dis 2013 ; 72:1830 – 5 . 35 Navarra SV et al . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus : a randomised , placebo-controlled , phase 3 trial . Lancet 2011 ; 377:721 – 31 . 36 Furie R et al . A phase III , randomized , placebocontrolled study of belimumab , a monoclonal antibody that
inhibits B lymphocyte stimulator , in patients with systemic lupus erythematosus . Arthritis Rheum 2011 ; 63:3918 – 30 . 37 Baker KP et al . Generation and characterization of LymphoStat-B , a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator . Arthritis Rheum 2003 ; 48:3253 – 65 . 38 Terrier B et al . Safety and efficacy of rituximab in systemic lupus erythematosus : results from 136 patients from the French AutoImmunity and Rituximab registry . Arthritis Rheum 2010 ; 62:2458 – 66 . 39 Diaz-Lagares C et al . Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis : pooled data from European cohorts . Autoimmun Rev 2012 ; 11:357 – 64 . 40 Boletis JN et al . Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis : a long-term prospective study . Nephrol Dial Transplant 2009 ; 24:2157 – 60 . 41 Jonsdottir T et al . Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion : pooled data from two cohorts . Rheumatology ( Oxford ) 2010 ; 49:1502 – 4 . 42 Jonsdottir T et al . Rituximabtreated membranous lupus nephritis : clinical outcome and effects on electron dense deposits . Ann Rheum Dis 2011 ; 70:1172 – 3 . 43 Li EK et al . Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis ? Rheumatology ( Oxford ) 2009 ; 48:892 – 8 . 44 Pepper R et al . Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids . Nephrol Dial Transplant 2009 ; 24:3717 – 23 . 45 Sfikakis PP et al . Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand : an open-label trial . Arthritis Rheum 2005 ; 52:501 – 13 . 46 Vigna-Perez M et al . Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy : a pilot study . Arthritis Res Ther 2006 ; 8 : R83 . 47 Leandro MJ et al . An open study of B lymphocyte depletion in systemic lupus erythematosus . Arthritis Rheum 2002 ; 46:2673 – 7 . 48 Looney RJ et al . B cell depletion as a novel treatment for systemic lupus erythematosus : a phase I / II dose-escalation trial of rituximab . Arthritis Rheum 2004 ; 50:2580 – 9 . 49 Leandro MJ et al . B-cell depletion in the treatment of patients with systemic lupus erythematosus : a longitudinal analysis of 24 patients . Rheumatology ( Oxford ) 2005 ; 44:1542 – 5 . 50 Ng KP et al . Repeated B cell depletion in treatment of refractory systemic lupus erythematosus . Ann Rheum Dis 2006 ; 65:942 – 5 . 51 Jonsdottir T et al . Treatment of refractory SLE with rituximab plus cyclophosphamide : clinical effects , serological changes , and predictors of response . Ann Rheum Dis 2008 ; 67:330 – 4 . 52 Jonsdottir T et al . Long-term follow-up in lupus nephritis patients treated with rituximab – clinical and histopathological response . Rheumatology ( Oxford ) 2013 ; 52:847 – 55 . 53 van Vollenhoven RF et al . Biopsy-verified response of severe lupus nephritis to treatment with
rituximab ( anti-CD20 monoclonal antibody ) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone . Scand J Rheumatol 2004 ; 33:423 – 7 . 54 Rovin BH et al . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis : the Lupus Nephritis Assessment with Rituximab study . Arthritis Rheum 2012 ; 64:1215 – 26 . 55 Merrill JT et al . Efficacy and safety of rituximab in moderatelyto-severely active systemic lupus erythematosus : the randomized , double-blind , phase II / III systemic lupus erythematosus evaluation of rituximab trial . Arthritis Rheum 2010 ; 62:222 – 33 . 56 Bertsias GK et al . Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association ( EULAR / ERA-EDTA ) recommendations for the management of adult and paediatric lupus nephritis . Ann Rheum Dis 2012 ; 71:1771 – 82 . 57 Hahn BH et al . American College of Rheumatology guidelines for screening , treatment , and management of lupus nephritis . Arthritis Care Res ( Hoboken ) 2012 ; 64:797 – 808 . 58 Ramos-Casals M et al . Off-label use of rituximab in 196 patients with severe , refractory systemic autoimmune diseases . Clin Exp Rheumatol 2010 ; 28:468 – 76 . 59 Witt M et al . Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus ( SLE ) – results from a nationwide cohort in Germany ( GRAID ). Lupus 2013 ; 22:1142 – 9 . 60 Ryden-Aulin M et al . Off-label use of rituximab for systemic lupus erythematosus in Europe . Lupus Sci Med 2016 ; 3 : e000163 . 61 van Vollenhoven RF et al . Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate : results of a phase II , randomized , placebocontrolled trial . Arthritis Rheum 2011 ; 63:1782 – 92 . 62 Ginzler EM et al . Atacicept in combination with MMF and corticosteroids in lupus nephritis : results of a prematurely terminated trial . Arthritis Res Ther 2012 ; 14 : R33 . 63 Furie RA et al . A phase 2 , randomised , placebo-controlled clinical trial of blisibimod , an inhibitor of B cell activating factor , in patients with moderate-to-severe systemic lupus erythematosus , the PEARL-SC study . Ann Rheum Dis 2015 ; 74:1667 – 75 . 64 Isenberg DA et al . Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus : results from ILLUMINATE-1 , a 52-week , phase III , multicentre , randomised , double-blind , placebocontrolled study . Ann Rheum Dis 2016 ; 75:323 – 31 . 65 Merrill JT et al . Efficacy and safety of subcutaneous tabalumab , a monoclonal antibody to B-cell activating factor , in patients with systemic lupus erythematosus : results from ILLUMINATE-2 , a 52-week , phase III , multicentre , randomised , double-blind , placebocontrolled study . Ann Rheum Dis 2016 ; 75:332 – 40 . 66 Gatto M et al . Success and failure of biological treatment in systemic lupus erythematosus : A critical analysis . J Autoimmun 2016 ; 74:94-105 . 67 Houssiau FA , Doria A . Targeting BAFF / BLyS in lupus : is the glass half-full or half-empty ? Ann Rheum Dis 2016 ; 75:321 – 2 .
68 Wallace DJ et al . Efficacy and safety of epratuzumab in patients with moderate / severe flaring systemic lupus erythematosus : results from two randomized , double-blind , placebo-controlled , multicentre studies ( ALLEVIATE ) and follow-up . Rheumatology ( Oxford ) 2013 ; 52:1313 – 22 . 69 Wallace DJ et al . Efficacy and safety of epratuzumab in patients with moderate / severe active systemic lupus erythematosus : results from EMBLEM , a phase IIb , randomised , double-blind , placebo-controlled , multicentre study . Ann Rheum Dis 2014 ; 73:183 – 90 . 70 Clowse MEB et al . Efficacy and safety of epratuzumab in patients with moderate-to-severe systemic lupus erythematosus : Results from two phase 3 randomized , placebocontrolled trials [ abstract ]. Arthritis Rheumatol 2015 ; 67 . 71 Liang B et al . Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus . Immunology 2006 ; 119:296 – 305 . 72 Kiberd BA . Interleukin-6 receptor blockage ameliorates murine lupus nephritis . J Am Soc Nephrol 1993 ; 4:58 – 61 . 73 Rovin BH et al . A Multicenter , randomized , double-blind , placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab ( CNTO 136 ) in patients with active lupus nephritis . Arthritis Rheumatol 2016 ; 68:2174 – 83 . 74 Illei GG et al . Tocilizumab in systemic lupus erythematosus : data on safety , preliminary efficacy , and impact on circulating plasma cells from an open-label phase I dosage-escalation study . Arthritis Rheum 2010 ; 62:542 – 52 . 75 Ronnblom L , Pascual V . The innate immune system in SLE : type I interferons and dendritic cells . Lupus 2008 ; 17:394 – 9 . 76 Khamashta M et al . Sifalimumab , an anti-interferonalpha monoclonal antibody , in moderate to severe systemic lupus erythematosus : a randomised , double-blind , placebocontrolled study . Ann Rheum Dis 2016 ; 75:1909 – 16 . 77 Kalunian KC et al . A Phase II study of the efficacy and safety of rontalizumab ( rhuMAb interferonalpha ) in patients with systemic lupus erythematosus ( ROSE ). Ann Rheum Dis 2016 ; 75:196 – 202 . 78 Furie R et al . Anifrolumab , an anti-interferon alpha receptor monoclonal antibody , in moderate to severe systemic lupus erythematosus ( SLE ) [ abstract ]. Arthritis Rheumatol 2015 ; 67 . 79 Merrill JT et al . The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus : results of a twelvemonth , multicenter , exploratory , phase IIb , randomized , doubleblind , placebo-controlled trial . Arthritis Rheum 2010 ; 62:3077-87 . 80 van Vollenhoven RF , Parodis I , Levitsky A . Biologics in SLE : towards new approaches . Best Pract Res Clin Rheumatol 2013 ; 27:341 – 9 . 81 Furie R et al . Efficacy and safety of abatacept in lupus nephritis : a twelve-month , randomized , double-blind study . Arthritis Rheumatol 2014 ; 66:379 – 89 . 82 Wofsy D , Hillson JL , Diamond B . Abatacept for lupus nephritis : alternative definitions of complete response support conflicting conclusions . Arthritis Rheum 2012 ; 64:3660 – 5 .
22
HHE 2018 | hospitalhealthcare . com